Highlights
- Market Cap
- $190.91M
- Enterprise Value
- $445.53M
- EPS (TTM)
- -$4.21
- Total Revenue (TTM)
- $727.33M
- Gross Profit (TTM)
- $314.29M
- EBITDA (TTM)
- -$57.30M
- Year Range
- $4.72 - $13.74
- Target Price
- $12.50
- ROA (TTM)
- -7.94%
- ROE (TTM)
- -12.91%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in NeoGenomics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
NeoGenomics, Inc. (NEO) has returned -36.90% so far this year and -21.81% over the past 12 months. Over the last ten years, NEO has returned 0.74% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
NeoGenomics, Inc.
- 1D
- 3.06%
- 1M
- -24.52%
- YTD
- -36.90%
- 6M
- -3.89%
- 1Y
- -21.81%
- 3Y*
- -24.75%
- 5Y*
- -31.31%
- 10Y*
- 0.74%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 16, 2004, NEO's average daily return is +0.20%, while the average monthly return is +2.56%. At this rate, your investment would double in approximately 2.3 years.
Historically, 51% of months were positive and 49% were negative. The best month was Aug 2025 with a return of +81.4%, while the worst month was Mar 2022 at -43.3%. The longest winning streak lasted 11 consecutive months, and the longest losing streak was 10 months.
On a daily basis, NEO closed higher 44% of trading days. The best single day was Mar 17, 2004 with a return of +97.7%, while the worst single day was Mar 22, 2004 at -37.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.55% | -18.49% | -24.52% | -36.90% | |||||||||
| 2025 | -13.23% | -30.14% | -5.01% | -32.61% | 13.84% | 0.41% | -33.79% | 81.40% | -12.07% | 26.55% | 23.85% | -2.81% | -28.64% |
| 2024 | -8.22% | 5.05% | 0.77% | -11.45% | -1.51% | 1.17% | 27.83% | -6.82% | -10.71% | -7.86% | 30.46% | -7.05% | 1.85% |
| 2023 | 28.57% | 41.84% | 3.32% | -16.03% | 17.51% | -6.46% | 7.84% | -13.27% | -18.16% | 13.98% | 29.60% | -10.95% | 75.11% |
| 2022 | -33.94% | -5.01% | -43.25% | -22.22% | -10.90% | -3.21% | 24.17% | -0.69% | -14.33% | -11.67% | 47.40% | -17.57% | -72.92% |
| 2021 | -1.52% | -3.87% | -5.38% | 1.58% | -16.25% | 10.09% | 2.06% | 5.47% | -0.78% | -4.64% | -25.52% | -0.41% | -36.63% |
Benchmark Metrics
NeoGenomics, Inc. has an annualized alpha of 54.95%, beta of 0.72, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 17, 2004.
- This stock captured 136.18% of S&P 500 Index gains and 109.54% of its losses — amplifying both gains and losses, but participating more in upside than downside.
- R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 54.95%
- Beta
- 0.72
- R²
- 0.02
- Upside Capture
- 136.18%
- Downside Capture
- 109.54%
Return for Risk
Risk / Return Rank
NEO ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NeoGenomics, Inc. (NEO) and compare them to a chosen benchmark (S&P 500 Index).
| NEO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.31 | 0.90 | -1.21 |
Sortino ratioReturn per unit of downside risk | 0.02 | 1.39 | -1.36 |
Omega ratioGain probability vs. loss probability | 1.00 | 1.21 | -0.21 |
Calmar ratioReturn relative to maximum drawdown | -0.43 | 1.40 | -1.83 |
Martin ratioReturn relative to average drawdown | -0.96 | 6.61 | -7.56 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore NEO risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeoGenomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeoGenomics, Inc. was 91.92%, occurring on Jul 31, 2025. The portfolio has not yet recovered.
The current NeoGenomics, Inc. drawdown is 87.61%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.92% | Feb 16, 2021 | 1120 | Jul 31, 2025 | — | — | — |
| -85.29% | Mar 22, 2004 | 465 | Jan 24, 2006 | 135 | Aug 7, 2006 | 600 |
| -72.14% | Nov 16, 2006 | 533 | Dec 30, 2008 | 143 | Jul 27, 2009 | 676 |
| -52.38% | Jul 28, 2009 | 271 | Aug 23, 2010 | 488 | Jul 30, 2012 | 759 |
| -49.64% | Apr 2, 2013 | 98 | Aug 19, 2013 | 100 | Jan 10, 2014 | 198 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeoGenomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeoGenomics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NEO relative to other companies in the Diagnostics & Research industry. Currently, NEO has a P/S ratio of 0.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NEO in comparison with other companies in the Diagnostics & Research industry. Currently, NEO has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |